Myeloma, Plasma-Cell clinical trials at UC Cancer
1 research study open to eligible people
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations
open to eligible people ages 18 years and up
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia, acute lymphocytic leukemia with KMT2A/ MLL1r, NPM1 and other mutations.
at UC Davis UC Irvine UCLA